PRODUCT LIST
Immunizations to help meet the needs of eligible patients
Select a brand to learn more.
Please see Important Safety Information and Prescribing Information for each brand using the links below.
Explore More Sanofi Products
View the full portfolio of products, including adult vaccines.
IMMUNIZATION SCHEDULE
Sample Sanofi WellChild immunization schedule
Adapted child and adolescent immunization schedule for ages 18 years or younger1-4
For full recommendations, which include important guidance and catch-up schedules, visit the CDC website.
| Immunization | Birth | 1 month |
2 months |
4 months |
6 months |
9 months |
12 months |
15 months |
18 months |
19-23 months |
1-3 years |
4-6 years |
7-10 years |
11-12 years |
13-15 years |
16 years |
17-18 years |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb) |
|
||||||||||||||||
| Hepatitis B (HepB) |
|
||||||||||||||||
| Diphtheria, tetanus, and acellular pertussis (DTaP: <7 yrs) |
|
|
|||||||||||||||
| Inactivated poliovirus (IPV: <18 yrs) | |||||||||||||||||
| Haemophilus influenzae type b (Hib) | |||||||||||||||||
| Rotavirus (RV): RV1 (2-dose series); RV5 (3-dose series) | |||||||||||||||||
| Pneumococcal conjugate (PCV13) | |||||||||||||||||
| Influenza (IIV3) |
 †
|
||||||||||||||||
| Influenza (LAIV3) | |||||||||||||||||
| Measles, mumps, rubella (MMR) | |||||||||||||||||
| Varicella (VAR) | |||||||||||||||||
| Hepatitis A (HepA) | |||||||||||||||||
| Meningococcal (MenACWY-TT ≥2 yrs) |
|
||||||||||||||||
| Tetanus, diphtheria, and acellular pertussis (Tdap: >7 yrs) |
|
||||||||||||||||
| Human papillomavirus (HPV) | |||||||||||||||||
| Meningococcal B | |||||||||||||||||
DTaP=diphtheria, tetanus, and acellular pertussis; HepA=hepatitis A; HepB=hepatitis B; Hib=haemophilus influenzae type b; HPV=human paplllomavirus; IIV3=trivalent inactivated influenza vaccine; IPV=inactivated poliovirus; LAIV3=trivalent live attenuated influenza vaccine; MenACWY-TT=meningococcal ACWY TT; MMR=measles, mumps, rubella; PCV=pneumococcal conjugate vaccine; RV=rotavirus; Tdap=tetanus, diphtheria, and acellular pertussis; VAR=varicella.
*The Advisory Committee on Immunization Practices (ACIP) recommends 1 dose of Beyfortus for all infants aged <8 months born during or entering their first RSV season (50 mg for infants weighing <5 kg and 100 mg for infants weighing ≥5 kg). ACIP recommends 1 dose of Beyfortus (200 mg administered as 2 IM injections [2 x 100 mg]) for children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season. See https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm.2
†CDC recommends eligible children 6 months to 8 years old may need two doses of flu vaccine. Children in this age group getting vaccinated for the first time, those who have only previously received one dose of flu vaccine, and those whose flu vaccination history is unknown should get two doses of vaccine this season. For those children it is recommended they get the first dose as soon as vaccine is available, because the second dose needs to be given at least 4 weeks after the first. Your child’s health care provider can tell you if your child needs two doses. See https://www.cdc.gov/flu/highrisk/children.htm#types.
References: 1. Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age: recommendations for ages 18 years or younger, United States, 2024. Accessed January 27, 2025. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 2. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:920–925. 3. Vaxelis. Prescribing Information. MSP Vaccine Company. 4. Fluzone. Prescribing Information. Sanofi Pasteur Inc.